About Thrive Earlier Detection
Thrive Earlier Detection is a company based in Cambridge (United States) founded in 2019 was acquired by Exact Sciences in October 2020. Thrive Earlier Detection has raised $367 million across 3 funding rounds from investors including Exact Sciences, Intermountain Healthcare and Brown Advisory. The company has 138 employees as of December 31, 2022. Thrive Earlier Detection operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Cambridge, United States
- Employees 138 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Thrive Earlier Detection Corp
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$367 M (USD)
in 3 rounds
-
Latest Funding Round
$257 M (USD), Series B
Jul 29, 2020
-
Investors
Exact Sciences
& 20 more
-
Employee Count
138
as on Dec 31, 2022
-
Acquired by
Exact Sciences
(Oct 27, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Thrive Earlier Detection
Unlock access to complete
Unlock access to complete
Leadership Team
105 people
Software Development Team
103 people
Screening Team
78 people
Senior Team
62 people
Sales and Marketing
30 people
Data Analysis and Operations Team
29 people
Human Resources and Administration
28 people
Operations Team
23 people
Unlock access to complete
Funding Insights of Thrive Earlier Detection
Thrive Earlier Detection has successfully raised a total of $367M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $257 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Thrive Earlier Detection
Thrive Earlier Detection has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Exact Sciences, Intermountain Healthcare and Brown Advisory.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Thrive Earlier Detection
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Thrive Earlier Detection
Investment portfolio details for Thrive Earlier Detection
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Thrive Earlier Detection
Detailed financials for Thrive Earlier Detection
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Thrive Earlier Detection Comparisons
Peer comparison for Thrive Earlier Detection
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Thrive Earlier Detection
Thrive Earlier Detection operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of Thrive Earlier Detection
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Thrive Earlier Detection
Complete news archive for Thrive Earlier Detection
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Thrive Earlier Detection
Thrive Earlier Detection was founded in 2019.
Thrive Earlier Detection is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Thrive Earlier Detection is a funded company, having raised a total of $367M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Thrive Earlier Detection is 138.
Thrive Earlier Detection was founded in 2019 and is based in Cambridge, United States. Operations center on the biotechnology sector, where a blood-based liquid biopsy test is developed for detecting multiple cancers. DNA mutations and protein abnormalities associated with cancer are analyzed through this test. The approach supports treatment by enabling earlier identification in clinical settings.
Thrive Earlier Detection's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
Thrive Earlier Detection has 21 investors. Key investors include Exact Sciences, Intermountain Healthcare, Brown Advisory, T. Rowe Price, and HHS.